Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
<p><strong>Background</strong> Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC).</p...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2018
|
| _version_ | 1797081745460297728 |
|---|---|
| author | Madi, A Fisher, D Maughan, T Colley, J Meade, A Maynard, J Humphreys, V Wasan, H Adams, R Idziaszczyk, S Harris, R Kaplan, R Cheadle, J |
| author_facet | Madi, A Fisher, D Maughan, T Colley, J Meade, A Maynard, J Humphreys, V Wasan, H Adams, R Idziaszczyk, S Harris, R Kaplan, R Cheadle, J |
| author_sort | Madi, A |
| collection | OXFORD |
| description | <p><strong>Background</strong> Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC).</p> <p><strong>Methods</strong> We analysed more than 200 potentially functional, common, inherited variants in genes within the 5FU, capecitabine, oxaliplatin and DNA repair pathways, together with four rare dihydropyrimidine dehydrogenase (DPYD) variants, in 2183 aCRC patients treated with oxaliplatin-fluoropyrimidine chemotherapy with, or without, cetuximab (from MRC COIN and COIN-B trials). Primary end-points were response, any toxicity and peripheral neuropathy. We had >85% power to detect odds ratios (ORs) = 1.3 for variants with minor allele frequencies >20%.</p> <p><strong>Results</strong> Variants in DNA repair genes (Asn279Ser in EXO1 and Arg399Gln in XRCC1) were most associated with response (OR 1.9, 95% confidence interval [CI] 1.2–2.9, P = 0.004, and OR 0.7, 95% CI 0.5–0.9, P = 0.003, respectively). Common variants in DPYD (Cys29Arg and Val732Ile) were most associated with toxicity (OR 0.8, 95% CI 0.7–1.0, P = 0.008, and OR 1.6, 95% CI 1.1–2.1, P = 0.006, respectively). Two rare DPYD variants were associated with increased toxicity (Asp949Val with neutropenia, nausea and vomiting, diarrhoea and infection; IVS14+1G>A with lethargy, diarrhoea, stomatitis, hand-foot syndrome and infection; all ORs > 3). Asp317His in DCLRE1A was most associated with peripheral neuropathy (OR 1.3, 95% CI 1.1–1.6, P = 0.003). No common variant associations remained significant after Bonferroni correction.</p> <p><strong>Conclusions</strong> DNA repair genes may play a significant role in the pharmacogenetics of aCRC. Our data suggest that both common and rare DPYD variants may be associated with toxicity to fluoropyrimidine-based chemotherapy.</p> |
| first_indexed | 2024-03-07T01:18:19Z |
| format | Journal article |
| id | oxford-uuid:8f797097-4e22-4525-85a3-fcbe229b919a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:18:19Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:8f797097-4e22-4525-85a3-fcbe229b919a2022-03-26T23:04:34ZPharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8f797097-4e22-4525-85a3-fcbe229b919aEnglishSymplectic Elements at OxfordElsevier2018Madi, AFisher, DMaughan, TColley, JMeade, AMaynard, JHumphreys, VWasan, HAdams, RIdziaszczyk, SHarris, RKaplan, RCheadle, J<p><strong>Background</strong> Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC).</p> <p><strong>Methods</strong> We analysed more than 200 potentially functional, common, inherited variants in genes within the 5FU, capecitabine, oxaliplatin and DNA repair pathways, together with four rare dihydropyrimidine dehydrogenase (DPYD) variants, in 2183 aCRC patients treated with oxaliplatin-fluoropyrimidine chemotherapy with, or without, cetuximab (from MRC COIN and COIN-B trials). Primary end-points were response, any toxicity and peripheral neuropathy. We had >85% power to detect odds ratios (ORs) = 1.3 for variants with minor allele frequencies >20%.</p> <p><strong>Results</strong> Variants in DNA repair genes (Asn279Ser in EXO1 and Arg399Gln in XRCC1) were most associated with response (OR 1.9, 95% confidence interval [CI] 1.2–2.9, P = 0.004, and OR 0.7, 95% CI 0.5–0.9, P = 0.003, respectively). Common variants in DPYD (Cys29Arg and Val732Ile) were most associated with toxicity (OR 0.8, 95% CI 0.7–1.0, P = 0.008, and OR 1.6, 95% CI 1.1–2.1, P = 0.006, respectively). Two rare DPYD variants were associated with increased toxicity (Asp949Val with neutropenia, nausea and vomiting, diarrhoea and infection; IVS14+1G>A with lethargy, diarrhoea, stomatitis, hand-foot syndrome and infection; all ORs > 3). Asp317His in DCLRE1A was most associated with peripheral neuropathy (OR 1.3, 95% CI 1.1–1.6, P = 0.003). No common variant associations remained significant after Bonferroni correction.</p> <p><strong>Conclusions</strong> DNA repair genes may play a significant role in the pharmacogenetics of aCRC. Our data suggest that both common and rare DPYD variants may be associated with toxicity to fluoropyrimidine-based chemotherapy.</p> |
| spellingShingle | Madi, A Fisher, D Maughan, T Colley, J Meade, A Maynard, J Humphreys, V Wasan, H Adams, R Idziaszczyk, S Harris, R Kaplan, R Cheadle, J Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title_full | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title_fullStr | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title_full_unstemmed | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title_short | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| title_sort | pharmacogenetic analyses of 2183 patients with advanced colorectal cancer potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy |
| work_keys_str_mv | AT madia pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT fisherd pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT maughant pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT colleyj pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT meadea pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT maynardj pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT humphreysv pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT wasanh pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT adamsr pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT idziaszczyks pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT harrisr pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT kaplanr pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy AT cheadlej pharmacogeneticanalysesof2183patientswithadvancedcolorectalcancerpotentialroleforcommondihydropyrimidinedehydrogenasevariantsintoxicitytochemotherapy |